Are all human-derived follicle-stimulating hormone products the same? A systematic review and meta-analysis using direct and adjusted indirect analyses, to determine whether Fostimon®is more efficient than Metrodin-HP®
- 19 May 2011
- journal article
- review article
- Published by Taylor & Francis in Gynecological Endocrinology
- Vol. 28 (2) , 94-101
Abstract
Background. Randomized trials (RCTs) and systematic reviews have challenged the claim for superiority of recombinant follicle-stimulating hormone (recFSH) compared with human-derived FSH (hFSH). Even so, much of the evidence comes from unavailable products. If the efficacy of the currently available Fostimon® is superior, the off-market Metrodin-HP®, then data from the latter should not be used, gauge of the former. Methods. Electronic/hand searches were performed to identify RCTs comparing Fostimon® vs. Metrodin-HP® or either product with recFSH. Primary outcomes were live-birth rate (LBR), ongoing pregnancy rate (OPR), and OPR/LBR. Secondary outcomes were clinical pregnancy rate (CPR), multiple pregnancy rate (MPR), ovarian hyperstimulation syndrome (OHSS), abortion rates, and cycle demographics. Data were extracted, allowed for an intention-to-treat analysis, and meta-analyzed using combined direct/adjusted indirect methods. Results. Twenty-two RCTs met the inclusion criteria: Fostimon® vs. Metrodin-HP® (n = 2); Fostimon® vs. recFSH (n = 8); and Metrodin-HP® vs. recFSH (n = 12). LBR (odds ratio = 1.72; 95% confidence interval = 1.05–2.80), OPR/LBR, and CPR were all significantly higher favoring Fostimon®. OPR, MPR, OHSS, and miscarriage rates were not significantly different. Pooled results for cycle demographics were not reported due to high heterogeneity. Conclusions. Fostimon® is superior to Metrodin-HP® regarding clinical outcomes. Therefore, care should be taken not to assume that all hFSH products have the same efficacy.Keywords
This publication has 30 references indexed in Scilit:
- IVF Outcomes with Either Highly Purified FSH vs. Recombinant FSH in Down-Regulated Normogonadotrophic Women: A Prospective Comparative Study in a Developing Country and Meta-AnalysisThe Open Women' S Health Journal, 2009
- Clinical efficacy of highly purified urinary FSH versus recombinant FSH in volunteers undergoing controlled ovarian stimulation for in vitro fertilization: a randomized, multicenter, investigator-blind trialFertility and Sterility, 2009
- P-794: Recent clinical evidence for selecting u-FSH or r-FSH in ARTFertility and Sterility, 2006
- Urinary follicle-stimulating hormone (FSH) is more effective than recombinant FSH in older women in a controlled randomized studyFertility and Sterility, 2006
- An open, prospective, randomized, multicenter study to compare recombinant human follicle stimulating hormone (rec-FSH; follitropin-β; Puregon® solution) with highly purified urinary FSH (uFSH, urofollitropin (highly purified), Metrodin® HP) in Chinese women undergoing fertilization (IVF)Fertility and Sterility, 2004
- FSH isoform composition of commercial gonadotrophin preparations: a neglected aspect?Reproductive BioMedicine Online, 2004
- Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analysesBMJ, 2003
- Intact follicle culture: what it can tell us aabout the roles of FSH glycoforms during follicle developmentReproductive BioMedicine Online, 2002
- Ovarian stimulation during assisted reproduction treatment: a comparison of recombinant and highly purified urinary human FSHHuman Reproduction, 2000
- A prospective, randomized, controlled clinical study of a new subcutaneous, purified, urinary FSH preparation for controlled ovarian hyperstimulation inin vitrofertilizationGynecological Endocrinology, 2000